LYTIX BIOPHARMA AS – MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER

11 Dec 2025 13:39 CET

Oslo, Norway, 11 December 2025: Primary insider Øystein Rekdal, Chief Executive
Officer of Lytix Biopharma AS, has today acquired 10,000 shares in Lytix
Biopharma AS at a price of NOK 9.9984 per share. Following the transaction,
Øystein Rekdal holds 176,179 shares in Lytix Biopharma AS.


Disclosure regulation:
This information is subject to the disclosure requirements pursuant to article
19 of the EU Market Abuse Regulation and section 5-12 of the Norwegian
Securities Trading Act.


For more information, please contact:
Gjest Breistein, CFO
+47 952 60 512
gjest.breistein@lytixbiopharma.com


About Lytix Biopharma
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly differentiated oncolytic molecule platform based on world-leading
research in host-defense peptide-derived molecules. Lytix Biopharma’s lead
product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule
representing a new approach to maintaining durable anti-cancer immunity. Lytix
Biopharma has a pipeline of molecules that work across multiple cancer
indications and treatment settings, both as mono- and combination therapy. Lytix
is listed on Euronext Growth Oslo under the ticker LYTIX.
Visit www.lytixbiopharma.com.

More information:
Access the news on Oslo Bors NewsWeb site

661716_Lytix - Øystein Rekdal - Mandatory notification of trade.pdf